Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes

Diabetes Care

Volumn 34, Issue 12, 2011, Pages 2560-2566

  Meininger, Gary E ^a,c   Scott, Russell ^b   Alba, Maria ^a,c   Shentu, Yue ^a   Luo, Edmund ^a,d   Amin, Himal ^a   Davies, Michael J ^a   Kaufman, Keith D ^a   Goldstein, Barry J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d Forest Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; MK 0941; PLACEBO; UNCLASSIFIED DRUG; 3 ((6 (ETHYLSULFONYL) 3 PYRIDINYL)OXY) 5 (2 HYDROXY 1 METHYLETHOXY) N (1 METHYL 1H PYRAZOL 3 YL)BENZAMIDE; 3-((6-(ETHYLSULFONYL)-3-PYRIDINYL)OXY)-5-(2-HYDROXY-1-METHYLETHOXY)-N-(1-METHYL-1H-PYRAZOL-3-YL)BENZAMIDE; BENZAMIDE DERIVATIVE; ENZYME ACTIVATOR; GLARGINE; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN; SULFONE;

ADULT; ARTICLE; BODY WEIGHT; CATARACT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL CHEST PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; BENZAMIDES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENZYME ACTIVATORS; GLUCOKINASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INSULIN, LONG-ACTING; MIDDLE AGED; SULFONES;

EID: 81555210580     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1200     Document Type: Article

References (25)

1. Matschinsky FM, Magnuson MA, Zelent D, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006;55:1-12 (Pubitemid 43343293)
2. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009;8:399-416
3. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009;30:1512-1526
4. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003;301:370-373 (Pubitemid 36877072)
5. Camacho RC, Qureshi SA, Yang X, Eiki J, Zhang BB. Stimulation of insulin secretion and enhancement of insulin action, in vivo, by a small molecule glucokinase activator (Abstract). Diabetes 2009;58 (Suppl. 1):A388
6. Ohyama S, Takano H, Satow A, et al. A small molecule glucokinase activator lowers blood glucose in rats desensitized to sulfonylurea agents (Abstract). Diabetes 2009;58(Suppl. 1):A397
7. Bonadonna RC, Heise T, Arbet-Engels C, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010;95:5028-5036
8. Zhi J, Zhai S, Mulligan ME, et al. A novel glucokinase activator RO4389620 improved fasting and postprandial plasma glucose in type 2 diabetic patients (Abstract). Diabetologia 2008;51(Suppl. 1):S23
9. Migoya EM, Miller J, Maganti J, Gottesdiener K, Wagner JA. The glucokinase activator MK-0599 lowers plasma glucose concentrations in healthy non-diabetic subjects (Abstract). Diabetes 2009;58 (Suppl. 1):A31
10. Chylack LT Jr, Wolfe JK, Singer DM, et al.; The Longitudinal Study of Cataract Study Group. The Lens Opacities Classification System III. Arch Ophthalmol 1993;111: 831-836 (Pubitemid 23170599)
11. Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167-177
12. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130
13. Hodges JL, Lehmann EL. The efficiency of some nonparametric competitors of the t-test. Ann Math Stat 1956;27:324-335
14. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4: 213-226 (Pubitemid 15055349)
15. O'Doherty RM, Lehman DL, Télémaque-Potts S, Newgard CB. Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 1999;48:2022-2027 (Pubitemid 29458366)
16. Peter A, Stefan N, Cegan A, et al. Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 2011;96:E1126-E1130
17. Sparsø T, Andersen G, Nielsen T, et al. The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 2008;51: 70-75 (Pubitemid 50003447)
18. Orho-Melander M, Melander O, Guiducci C, et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 2008;57: 3112-3121
19. Kozian DH, Barthel A, Cousin E, et al. Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study. Horm Metab Res 2010;42: 502-506
20. Saxena R, Voight BF, Lyssenko V, et al.; Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-1336
21. Vaxillaire M, Cavalcanti-Proença C, Dechaume A, et al.; DESIR Study Group. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 2008; 57:2253-2257
22. Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009;18:4081-4088
23. Nakamura A, Terauchi Y, Ohyama S, et al. Impact of small-molecule glucokinase activator on glucose metabolism and β-cell mass. Endocrinology 2009;150: 1147-1154
24. Nakumura A, Shimazaki H, Ohyama S, et al. Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function. J Diabetes Invest 2011; 2:276-279
25. Ferre T, Riu E, Franckhauser S, Agudo J, Bosch F. Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia 2003;46:1662-1668 (Pubitemid 38005328)